Agios Pharmaceuticals, Inc. (LON:0HB0)
27.30
-0.20 (-0.73%)
At close: Dec 5, 2025
Agios Pharmaceuticals Employees
As of December 31, 2024, Agios Pharmaceuticals had 488 total employees, including 486 full-time and 2 part-time employees. The number of employees increased by 102 or 26.42% compared to the previous year.
Employees
488
Change (1Y)
102
Growth (1Y)
26.42%
Revenue / Employee
68.42K GBP
Profits / Employee
-612.97K GBP
Market Cap
1.21B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 488 | 102 | 26.42% |
| Dec 31, 2023 | 386 | -7 | -1.78% |
| Dec 31, 2022 | 393 | 1 | 0.26% |
| Dec 31, 2021 | 392 | -170 | -30.25% |
| Dec 31, 2020 | 562 | 26 | 4.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Agios Pharmaceuticals News
- 10 days ago - Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO Stock News - GuruFocus
- 12 days ago - Truist Securities Initiates Coverage on Agios Pharmaceuticals (AGIO) with a 'Buy' Rating | AGIO ... - GuruFocus
- 17 days ago - This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
- 17 days ago - Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
- 17 days ago - Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Trial Results - GuruFocus
- 17 days ago - Noteworthy Wednesday Option Activity: AGIO, VLO, AMTM - Nasdaq
- 17 days ago - Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility - Seeking Alpha
- 17 days ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript - Seeking Alpha